Generic Semaglutide in Canada: Pricing Guide and Cross-Border Notes for 2026
Canada is first G7 country with two approved Ozempic generics: Dr. Reddy's Apr 28, Apotex May 1, Sandoz Q3 2026. Expected 45-90% cheaper than brand.
Health Canada has approved two generic versions of semaglutide in five days, making Canada the first G7 country with multiple approved Ozempic generics. Dr. Reddy's Laboratories' filing cleared April 28, 2026. Apotex's followed on May 1. Seven additional submissions remain in Health Canada review, and Sandoz has confirmed a Q3 2026 commercial launch on its own filing.
The driver is patent timing. Canadian patent protection on key semaglutide molecules lapsed earlier than expected after a Novo Nordisk maintenance-fee issue, opening the generic pathway in a market that runs roughly a year ahead of European patent expiry and five-plus years ahead of US expiry. For Canadian patients, this is the first concrete pricing relief — generic prices are expected to run 45-90% below brand-name Ozempic and Wegovy.
For US patients reading this, the immediate practical relevance is limited (importation from Canada for personal use is legally constrained), but the Canadian market is a useful preview of what the US faces after December 2031 when key US patents expire. Watching how Canadian payers, prescribers, and patients adopt generic semaglutide gives the field a five-year window to plan for the analogous US transition.
This guide covers: approval timeline, expected generic pricing by manufacturer, payer coverage in Canada, cross-border purchase considerations for US patients, and how the Canadian patent timing compares with the rest of the world.
For full GLP-1 pricing context, see GLP-1 Pricing: May 2026. For US-specific generic-semaglutide expectations, the December 2031 US patent cliff is the relevant date — Canadian dynamics today preview that 2032+ market.
Health Canada approval timeline
Health Canada approved two generic semaglutide injection products within five days, making Canada the first G7 country with multiple approved Ozempic generics. Seven additional submissions are in review. The pace reflects Health Canada's willingness to move quickly once Canadian patent protection lapsed.
| Channel | Price | Source |
|---|---|---|
| First Generic — Dr. Reddy's Laboratories | Approved April 28, 2026 | Health Canada |
| Second Generic — Apotex | Approved May 1, 2026 | Health Canada |
| Additional Submissions | 7 in Health Canada review | CBC News |
| Sandoz Generic Launch (Confirmed) | Q3 2026 commercial launch | Bloomberg |
Expected generic pricing in Canada (CAD)
Canadian generic medications typically run 45-90% cheaper than brand-name equivalents under the federal regulatory framework. Brand Ozempic currently retails around CAD $300-400/mo in Canadian pharmacies (USD ~$210-285), so generic equivalents at 45-90% discounts will land in the CAD $30-200/mo range. Final pricing is set by individual manufacturers and varies by pharmacy.
| Channel | Price | Source |
|---|---|---|
| Brand Ozempic Canada (Baseline) | CAD $300-400/mo (~$210-285 USD) | Walk In Virtual Clinic |
| Generic Semaglutide (Expected Mid-Range) | CAD $90-220/mo (~$65-155 USD) | Felix |
| Generic Semaglutide (Expected Low-End) | CAD $30-90/mo (~$22-65 USD) | OverTheBorderMeds |
| Provincial Drug Plan Coverage | Plan-by-plan | Benefits and Pensions Monitor |
Patent context — why Canada is first
Canadian semaglutide patent timing diverged from the rest of the G7 due to a Novo Nordisk maintenance-fee issue. The standard semaglutide composition-of-matter patent in Canada lapsed years earlier than equivalent patents in the US, EU, and UK. The data-exclusivity period that protected the brand against generic entry expired on January 4, 2026, opening the regulatory pathway.
| Channel | Price | Source |
|---|---|---|
| Canadian Data Exclusivity Expiry | January 4, 2026 | Patent Lawyer Magazine |
| US Composition Patent | Expires December 2031 | Felix |
| EU Patent Expiry | Late 2026 - 2027 | Patent Lawyer Magazine |
| India Patent Expiry (Reference) | March 20, 2026 | Business Standard |
Cross-border considerations for US patients
Importing prescription medications from Canada for personal use sits in a legal gray zone in the US. FDA enforcement discretion has historically allowed small personal-use quantities through customs, but the agency has signaled tighter enforcement against compounded GLP-1 supply chains, and parallel enforcement on personal imports could escalate. The practical advice is that patients considering Canadian-sourced generic semaglutide should consult a US-licensed prescriber and a healthcare attorney before relying on cross-border supply for ongoing therapy.
| Channel | Price | Source |
|---|---|---|
| Personal-Use Import (Up to 90-day Supply) | Legal gray zone | OverTheBorderMeds |
| Cold-Chain Logistics Cost | $50-150 per shipment | OverTheBorderMeds |
| US-Licensed Prescriber Required | Yes | Endor Health |
What this means for the US 2032 generic transition
The Canadian market is a five-year preview of what the US semaglutide market will look like after December 2031 when key US patents expire. Watching how Canadian payers, generic manufacturers, prescribers, and patients adapt to multi-manufacturer generic competition gives the field a real-time data set for planning the analogous US transition. Key questions to track: how quickly do Canadian payers move to generics as first-line coverage; do brand-name Ozempic and Wegovy sustain market share through prescriber loyalty and patient preference for known molecules; what happens to compounded GLP-1 supply once a $30-90/mo generic is on shelves.
| Channel | Price | Source |
|---|---|---|
| US Patent Cliff | December 2031 | Felix |
| Novo Nordisk 2027 WAC Cut (Announced) | ~$675/mo | Novo Nordisk PR |
| Tirzepatide Patent Expiry | 2036 | Coherent Market Insights |
Which Canadian provinces and pharmacy chains to watch
Generic semaglutide rollout in Canada will move at the provincial level, with each province's formulary committee deciding when (and at what reimbursement level) to list generic versions. Ontario, British Columbia, and Quebec have historically moved fastest on generic uptake. Pharmacy chains Shoppers Drug Mart, Rexall, and London Drugs are the primary distribution points. Loblaw's PC Optimum pharmacy network and Costco Canada also stock GLP-1s and will likely transition to generic supply once available.
| Channel | Price | Source |
|---|---|---|
| Ontario Drug Benefit Program | Pending formulary decision | CBC News |
| British Columbia PharmaCare | Pending formulary decision | Benefits and Pensions Monitor |
| Quebec RAMQ | Pending formulary decision | CBC News |
| Private Insurance (Group Plans) | Plan-by-plan | Benefits and Pensions Monitor |